or Try an Advanced Search...

    Technical Analysis for PROK - ProKidney Corp.

    Grade Last Price % Change Price Change
    F 1.55 -3.13% -0.05
    PROK closed down 3.13 percent on Friday, November 1, 2024, on 53 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical PROK trend table...
    Date Alert Name Type % Chg
    New Downtrend Bearish 0.00%
    Down 3 Days in a Row Weakness 0.00%
    Down 4 Days in a Row Weakness 0.00%
    Lower Bollinger Band Touch Weakness 0.00%
    Oversold Stochastic Weakness 0.00%
    MACD Bearish Signal Line Cross Bearish -3.13%
    Stochastic Reached Oversold Weakness -3.13%
    Down 3 Days in a Row Weakness -3.13%
    Oversold Stochastic Weakness -3.13%
    Inside Day Range Contraction -7.74%
    Older End-of-Day Signals for PROK ...

       Recent Intraday Alerts

    Alert Time
    60 Minute Opening Range Breakdown about 17 hours ago
    Down 1% about 17 hours ago
    Fell Below Previous Day's Low about 19 hours ago
    Possible NR7 about 19 hours ago
    Up 2% about 21 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    PROK Chart by TradingView
    Basic chart:

    Profile

    ProKidney, a pioneer in the treatment of chronic kidney disease (CKD) through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney’s lead product candidate, REACT™ (Renal Autologous Cell Therapy), is a first-of-its-kind, patented disease-modifying autologous cellular therapy with the potential to not only slow and stabilize the progression of CKD, but in some cases drive meaningful improvement in kidney function. REACT™ has received Regenerative Medicine Advanced Therapy (RMAT) designation, as well as FDA and EMA guidance, supporting its ongoing Phase 3 clinical program, which launched in January 2022.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Life Sciences Health Sciences Pharmacy Cell Therapy FDA Kidney Disease Regenerative Medicine Breakthrough Therapy Chronic Kidney Disease Regenerative Medicine Advanced Therapy

    Is PROK a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Oct 22 Suvretta Capital Management's Strategic Acquisition in ProKidney Corp
    Oct 18 We're Not Very Worried About ProKidney's (NASDAQ:PROK) Cash Burn Rate
    Oct 14 ProKidney Announces Five Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2024
    Oct 9 ProKidney to Participate in the UBS Virtual Organ Restoration Day
    Sep 29 Wall Street Breakfast: The Week Ahead
    Sep 4 ProKidney drops Phase III CKD study to focus on US market and save up to $175m
    Sep 3 ProKidney revises Phase 3 program for lead asset
    Sep 3 ProKidney Announces Strategic Updates to its Phase 3 Program to Accelerate Rilparencel’s Registrational Path to Potential Approval in the U.S.
    Aug 27 ProKidney to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
    Aug 23 The Prognosis For ProKidney: Unclear
    See more PROK news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 4.44
    52 Week Low 1.12
    Average Volume 731,447
    200-Day Moving Average 2.14
    50-Day Moving Average 2.03
    20-Day Moving Average 1.76
    10-Day Moving Average 1.72
    Average True Range 0.14
    RSI (14) 35.90
    ADX 25.04
    +DI 14.35
    -DI 30.70
    Chandelier Exit (Long, 3 ATRs) 1.60
    Chandelier Exit (Short, 3 ATRs) 1.91
    Upper Bollinger Bands 2.00
    Lower Bollinger Band 1.52
    Percent B (%b) 0.07
    BandWidth 27.27
    MACD Line -0.10
    MACD Signal Line -0.09
    MACD Histogram -0.0087
    Fundamentals Value
    Market Cap 105.22 Million
    Num Shares 67.9 Million
    EPS -0.58
    Price-to-Earnings (P/E) Ratio -2.67
    Price-to-Sales 0.00
    Price-to-Book 91.32
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 1.77
    Resistance 3 (R3) 1.77 1.71 1.73
    Resistance 2 (R2) 1.71 1.65 1.70 1.72
    Resistance 1 (R1) 1.63 1.62 1.60 1.62 1.71
    Pivot Point 1.56 1.56 1.55 1.56 1.56
    Support 1 (S1) 1.48 1.51 1.45 1.48 1.39
    Support 2 (S2) 1.42 1.47 1.41 1.38
    Support 3 (S3) 1.34 1.42 1.37
    Support 4 (S4) 1.33